[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)].
A sample of 29 patients suffering from ischaemic cerebrovascular disorders was examined. Of these, 15 were treated with Ditazol (1200 mg/day in three administrations) and 14 with ASA (1 g a day in 2 administration). These patients were evaluated using serial Born and Cross tests to check ADP, Adrenaline and Collagen-induced platelet aggregation. The clinical follow-up lasted 22-34 months. As part of the laboratory evaluation, this sample was also compared with a group of 34 healthy volunteers. Ditazol was found to be an inhibitor of ADP, Adrenaline and Collagen-induced platelet aggregation: this effect constitutes clinical protection against recurrence of the complaint. Recurrence was 13.3% with Ditazol treated patients and 35.7% with ASA.